TD Cowen analyst Steven Ma raised the firm’s price target on BioLife Solutions to $26 from $20 and keeps a Buy rating on the shares. The firm updated its model to remove CBS (freezer) revenue given the upcoming divestiture and expect Q2 execution on conservative guide and improving backdrop.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.